X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES GLENMARK PHARMA VENUS REMEDIES/
GLENMARK PHARMA
 
P/E (TTM) x -7.6 18.7 - View Chart
P/BV x 0.1 3.3 3.5% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 VENUS REMEDIES   GLENMARK PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
GLENMARK PHARMA
Mar-17
VENUS REMEDIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs143993 14.4%   
Low Rs65729 8.9%   
Sales per share (Unadj.) Rs324.2325.5 99.6%  
Earnings per share (Unadj.) Rs6.439.3 16.3%  
Cash flow per share (Unadj.) Rs40.648.7 83.4%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs366.0159.2 229.9%  
Shares outstanding (eoy) m12.34282.17 4.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.6 12.1%   
Avg P/E ratio x16.221.9 74.0%  
P/CF ratio (eoy) x2.617.7 14.5%  
Price / Book Value ratio x0.35.4 5.2%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m1,282242,991 0.5%   
No. of employees `0000.913.0 7.0%   
Total wages/salary Rs m25116,408 1.5%   
Avg. sales/employee Rs Th4,430.17,083.9 62.5%   
Avg. wages/employee Rs Th278.01,265.4 22.0%   
Avg. net profit/employee Rs Th87.6855.1 10.2%   
INCOME DATA
Net Sales Rs m4,00091,857 4.4%  
Other income Rs m23374 6.1%   
Total revenues Rs m4,02392,230 4.4%   
Gross profit Rs m78520,367 3.9%  
Depreciation Rs m4222,644 15.9%   
Interest Rs m3442,373 14.5%   
Profit before tax Rs m4215,724 0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m-373,827 -1.0%   
Profit after tax Rs m7911,088 0.7%  
Gross profit margin %19.622.2 88.5%  
Effective tax rate %-87.924.3 -361.1%   
Net profit margin %2.012.1 16.4%  
BALANCE SHEET DATA
Current assets Rs m2,60668,746 3.8%   
Current liabilities Rs m1,98027,027 7.3%   
Net working cap to sales %15.645.4 34.4%  
Current ratio x1.32.5 51.7%  
Inventory Days Days12885 150.9%  
Debtors Days Days4396 45.2%  
Net fixed assets Rs m5,35324,132 22.2%   
Share capital Rs m123282 43.7%   
"Free" reserves Rs m4,39344,643 9.8%   
Net worth Rs m4,51644,925 10.1%   
Long term debt Rs m1,61845,363 3.6%   
Total assets Rs m8,291117,639 7.0%  
Interest coverage x1.17.6 14.7%   
Debt to equity ratio x0.41.0 35.5%  
Sales to assets ratio x0.50.8 61.8%   
Return on assets %5.111.4 44.6%  
Return on equity %1.824.7 7.1%  
Return on capital %6.319.1 32.8%  
Exports to sales %00-   
Imports to sales %18.40-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m736NA-   
Fx inflow Rs m056,152 0.0%   
Fx outflow Rs m7368,084 9.1%   
Net fx Rs m-73648,068 -1.5%   
CASH FLOW
From Operations Rs m9976,574 15.2%  
From Investments Rs m-461-7,124 6.5%  
From Financial Activity Rs m-5715,432 -10.5%  
Net Cashflow Rs m-351,992 -1.8%  

Share Holding

Indian Promoters % 32.9 48.3 68.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 6.9 2.6%  
FIIs % 0.6 34.4 1.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.5 632.4%  
Shareholders   20,121 56,727 35.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  CIPLA  TORRENT PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Tata Steel & Vedanta Top Losers(Closing)

Indian share markets erased early gains to end lower today, as the opposition parties tabled a no-confidence motion against Prime Minister Narendra Modi's government.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jul 18, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS